STATEMENT-III"

The Name of Drugs! Intermediates having Top Imports during 1992-93, *Bombay Port (April to Sept'92)*

S. No.	Name of the Item	Quantity	C.I.F. Value
1.	Recrystalised Insulin Plovin	1873.08 MOU	Rs. 21,51,78,870
2.	Penicillin G First Crystals (Drug Intmdt.)	291460.5 kg	Rs. 19,53,82,755
3.	Cefotaxime Sodium	2281.014 kg	Rs. 9,21,99,302
4.	Ampicillin Trihydrate	39390 kg	Rs. 8,68,70,801
5.	L-Base (Drug Intmdt.)	33525 kg	Rs. 7,43,40,293
6.	Tetracycline	137210 kg	Rs. 7,13,15,398
7.	Crystalline Insulin. Zinc	9.737 kg	Rs. 6,81,95,929
8.	Ceftazidine for Inj.	547.66 kg	Rs. 4,64,77,524
9.	Carbamezapine	22346 kg	Rs. 4,42,85,034
10.	Chloramphenicol Sodium Succinate	8440 kg	Rs. 2,92,94,174
11.	Analgin	100165kg	Rs. 2,91,27,461
12.	Anvikacin Sulphate	567 kg	Rs. 2,68,99,385
13.	Chloroquine salt (Bulk)	34165 kg	Rs. 2,68,35,818
14.	Isoplin HCl	4532.5 kg	Rs. 2,18,91,957
15.	Furazulodine	85300 kg	Rs. 2,07,20,658

Multinational Drug companies reluctant *to* invest in the Country

396. SHRI RAJNI RANJAN SAHU :
SHRIMATI SATYA BAHIN :

Will the PRIME MNISTER be pleased to state :

(a) whether if is a fact that most of the multinational drug companies are not willing to investment in the country;

(b) wheher it is also a fact that they are passing country's precious foreign exchange to their holding companies abroad by continuous improts at high over-invoiced prices;

(c) what was the import of each mult"-national company of drugs, thug inter-mediates and raw materials during the last three year?, year-wise;

(d) whether it is also a fact that they are not interested in basic; production in the country;

(e) what are the names of bulk drugs whose production was commenced by each multinational company during the last three year, year-wise; and

(f) whether any study of the above aspects have been carried out and if *so,* what are the findings on these issues in respect of muh national drug companies ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO) : (a) In the last few years a number of tetters of intent have been given to multinational drug companies. As such there is no reason to draw any such inference.

(b) No evidence of over-invoicing has come to notice.

(c) Company wise data of imports is not monitored.

(d) Under the provisions of the Drug Policy, all approvals for manufacture of bulk drugs in ire organised sector, including for multinational companies, are being given only from the prescribed basic stages.

(e) Names of the drugs for which industrial approvals have been given in the last three years is .given at statement. (See below) However, details of commencenment of production are not available.

(f) No special study on multinationals in the drugs sector has been carried out. The general policy of the Government is to encourage foreign investment in the country. A Background Note on Review of Drug Policy has been placed on the Table of the House, which deals with some of these issues.

STATEMENT

Name of the company	Name of Bulk Drug/Drug Intermediate
1990	
1. M/s. Reckitt & Colman	3, 5-Di-Benzyloxy Acetophenone
2. M/s. Pfizer Ltd.	Chloropropamide Tinidazole
3. M/s. Hoechst India	Glybenclamide Subs.
4. M/s. Eskayef	Cloxicillin Monohydrate
1991	
1. M/s. Hoechst India	Baralgan Ketone
2. M/s. Cibatul Ltd.	Diclofenac Sodium
	Acenolol
	Frusamide
	Trameinoprim
3. M/s. Duphar Interfran	Isoxcuprine Hydrochloride
1992	
1. M/s. Reckitt & Colman	Para-Chloro-Meta Xylenol
2. M/s. Glaxo	Ranitidine
3. M/s. Roussel India	Roxythromycin
4. M/s. Hoechst India	Fenbendazole

Liability of Drug Companies *as* arrear of Land. Re venue

397. SHRIMATI KAILASHPATI :
SHRI RAJNI RANJAN SAHU :

Will the PRIME MINISTER be pleased to state :

(a) what are the-ndetails of the cases of the drug companies which have been asked to discharge their liability of arrears of land revenue;

(b) when the orders were issued in each case;

(c) whether it is a fact that Government have with drawn such decision in respect of certain cases;

(d) whether it is also fact that the Development Commissioner (PI) has been siding with the companies in the matter of recovery and has failed to finalise and clinch any oase during the last! two years ; and

(e) what are the details of recovery and-fresh assessment during the last two years *?